Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Zevra Therapeutics Inc (ZVRA)

Zevra Therapeutics Inc (ZVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Zevra Therapeutics, Inc. to be Added to Nasdaq Biotechnology Index Effective December 23, 2024

Zevra Therapeutics to join the Nasdaq Biotechnology Index effective December 23, enhancing its visibility in the biotech sector.Quiver AI SummaryZevra Therapeutics, Inc. announced that it will be added...

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics Announces Organizational Changes to Enhance Focus on Rare Disease Therapies

Zevra Therapeutics announces organizational changes to enhance focus on rare disease therapeutics, consolidating leadership and streamlining operations.Quiver AI SummaryZevra Therapeutics, Inc. has announced...

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics Announces Organizational Changes

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics CEO Neil F. McFarlane to Participate in December Investor Events

Zevra Therapeutics announces CEO Neil McFarlane's participation in December investor events focused on rare diseases.Quiver AI SummaryZevra Therapeutics, Inc., a company focused on treating rare diseases,...

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics to Participate at Upcoming Investor Conferences

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics Announces Availability of MIPLYFFA™, First FDA-Approved Treatment for Niemann-Pick Disease Type C, Through AmplifyAssist™ Patient Support Program

Zevra Therapeutics announces MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, now available via AmplifyAssist support program.Quiver AI SummaryZevra Therapeutics, Inc. announced...

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics: Q3 Earnings Snapshot

Zevra Therapeutics: Q3 Earnings Snapshot

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

ZVRA : 8.49 (-0.59%)

Barchart Exclusives

Love Dividends? 2 Passive Income Stocks to Scoop Up Now.
These consistent dividend-paying stocks could be a good addition to your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar